ARPC1B

Across TCGA pan-cancer cohorts, ARPC1B Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ARPC1B data layer compared with 29 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ARPC1B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ARPC1B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, HNSC, and STAD are the cancer types where ARPC1B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.051	0.720	<.001	48	view →
HNSC	DFS	Median	All	0.156	0.713	<.001	33	view →
STAD	OS	Median	All	0.075	0.667	<.001	24	view →
ACC	OS	Median	All	0.214	0.802	.002	15	view →
UCEC	DFS	Median	All	1.000	0.623	.021	10	view →
COAD	DFS	Median	All	0.212	0.696	.009	5	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ARPC1B–BLCA (OS)

Open the BLCA breakdown →